Mannkind Corp MNKD

$3.34 -0.01 (-0.30%)

Valuation

Market cap
1,073,957,000
Revenue TTM
$348,970,000
Net income TTM
$5,860,000
PE ratio
0.00
Forward PE
—
Profit margin
1.68%
Debt to equity
-6.28

Trading

Volume
2,368,017
Avg volume
4,282,984
Day's range
$3.28 – $3.37
Shares out
321,544,000
Stochastic %K
35%
Beta
1.10
Analysts
Strong Sell
Price target
$7.97

Price

Company profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in...

Show more

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Phone
818 661 5000
Website
https://mannkindcorp.com
Address
1 Casper Street, Danbury, United States

Latest news

Stocktwits

chazbruin2 Sep 29, 7:59 PM
$MNKD +.005 again & again & again. No manipulation here SEC.
0 replies
AfrezzaFactsMatter Sep 29, 7:42 PM
$MNKD @kcphaeton You can't have a rational discussion with someone who is obviously mentally compromised. See, facts just don't register with people who are so emotionally tied to a stock that they will only believe what their diseased mind has formulated for them. If these individuals had any ability to think clearlyand logically, they'd know that these analysts are typically off the mark by a lot. Case in point. Look at what Wells Fargo had to say about Mannkind's one year target price when it initiated coverage on the company back in 2024. https://www.nasdaq.com/articles/wells-fargo-initiates-coverage-mannkind-mnkd-overweight-recommendation How close did the analyst get to that target price? How close has the analyst gotten at any point in time while covering the stock? A sane person would realize that something is not right with these analysts. But nope. The hard evidence of repeated missed price targets by almost every analyst is ignored by those who love to lie to themselves.
0 replies
kcphaeton Sep 29, 7:17 PM
$MNKD $UTHR Mr. CUCK we will see who is right SHORTLY…. But until then I Am waiting at the beach
0 replies
stevemano Sep 29, 7:12 PM
$MNKD $UTHR well. You too phaker fraudman. The clown that tells people to buy high and sell low. I will go with the Analysts. Not the circus 🎪 you are part of!! Keep acting clown 🤡!
0 replies
Dogcatfish Sep 29, 6:42 PM
$MNKD We are up a PENNY!
0 replies
grampslol Sep 29, 6:18 PM
$MNKD trade for pennies junk stock ... #afizzle
0 replies
kcphaeton Sep 29, 6:05 PM
$MNKD $UTHR dream on big boy.
0 replies
kcphaeton Sep 29, 5:54 PM
$MNKD $UTHR @Kuka sadly there is not bashing. Just fleeing for the exits. Martine will own it all very cheaply. $5.00 offer will seal the deal. Patience has paid off for Martine! Not so much for the rest of us. I can wait it out buy my guess is she will wait for PPS drop to $2.50 or less.
0 replies